title: Helicobacter pylori infection in Greenlandic patients with dyspepsia.
abstract: OBJECTIVE
  The aim was to evaluate the incidence of Helicobacter pylori (HP) infection in Greenland, to assess the value of the test "Helicobacter antigen in faeces" as a diagnostic tool and to determine the level of antibiotic resistance.
  
  
  METHODS
  100 consecutive patients with dyspepsia who visited for endoscopic gastric examination were included. The patients had to be born in Greenland and to be > or = 18 years old.
  
  
  METHODS
  Samples for HP antibody in blood, HP antigen in faeces, urease test on biopsies were collected from the patients. Gastric biopsies were cultured for HP bacteria, and antibiotic resistance was tested. Patients with positive urease test and/or antigen in faeces and/or positive culture were treated simultaneously with Amoxicillin, Metronidazole and Esomeprazole for 1 week. Patients with duodenal or gastric ulcer were endoscopically re-examined 8 weeks later. Patients with proven HP infection but without ulcer submitted a faeces sample 8 weeks after the eradication.
  
  
  RESULTS
  77 patients were considered HP infected, and received treatment. Only 32% of them were eradicated sufficiently.
  
  
  CONCLUSIONS
  HP antigen in faeces test is useful as a diagnostic tool and for control of therapy. A change in strategy of HP treatment in Greenland is a must, presumably preceded by an elucidation of microbial sensitivity.
authors.affiliation: Surgical Department, Dronning Ingrids Hospital, Greenland. jk.johansen@wanadoo.dk
authors.forename: Jens Kurt
authors.initials: JK
authors.lastname: Johansen
authors.forename: Ane
authors.initials: A
authors.lastname: Sehested
authors.forename: Torben
authors.initials: T
authors.lastname: Myrhøj
authors.forename: Karin
authors.initials: K
authors.lastname: Ladefoged
authors.forename: Karen A
authors.initials: KA
authors.lastname: Krogfelt
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D004415:Dyspepsia / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D064098:Esomeprazole / Q000627:therapeutic use; D006116:Greenland / Q000453:epidemiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D000658:Amoxicillin; D064098:Esomeprazole